Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 9/20 | 0.69 |
| ▸ | ITGB8 | P26012 | 6/20 | 0.69 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.58 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.58 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | TFPI | P10646 | 2/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540118 | 0.96 | ITGAV (0.74) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL30883996 | 0.96 | ITGAV (0.74) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL29540460 | 0.94 | ITGAV (0.68) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL29540413 | 0.93 | ITGAV (0.67) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL29811181 | 0.90 | ITGAV (0.59) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL29811168 | 0.88 | ITGAV (0.55) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL30883998 | 0.88 | ITGAV (0.64) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL29540531 | 0.88 | ITGAV (0.65) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL29933821 | 0.87 | ITGAV (0.53) | ITGAVITGB8ITGB6ITGB3ITGB5 | |
| SCHEMBL29540391 | 0.86 | ELANE (0.61) | ITGAVITGB8ITGB6ITGB3ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596105-B1 | LIGANDS FOR INTEGRIN .ALPHA.V.BETA.8, SYNTHESIS AND USES THEREOF | UNIV MUENCHEN TECH (DE) | 2023-12-27 | — | — | EP | claimed |
| US-11332498-B2 | Ligands for integrin αVβ8, synthesis and uses thereof | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2022-05-17 | — | — | US | claimed |
| EP-3596105-B1 | LIGANDS FOR INTEGRIN .ALPHA.V.BETA.8, SYNTHESIS AND USES THEREOF | UNIV MUENCHEN TECH (DE) | 2023-12-27 | — | — | EP | disclosed |
| US-11332498-B2 | Ligands for integrin αVβ8, synthesis and uses thereof | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332498-B2 | Ligands for integrin αVβ8, synthesis and uses thereof | ITGB3, ITGB8, ITGA8 | ITGAV 6/4885ITGB8 2/4885ITGB6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.